Join our daily newsletter At The Bell to receive exclusive market insights
- Clinuvel Pharmaceuticals (CUV) is progressing manufacturing of its adrenocorticotropic hormone (ACTH) product, NEURACTHEL
- The product will be made under current good manufacturing practices as the company finalises necessary work for a complete regulatory dossier
- The hormone is aimed to be used to treat neurological, endocrinological and degenerative disorders
- The company has engaged a manufacturing partner and strengthened its intellectual property portfolio as part of its broader strategy
- Shares are trading 2 per cent higher at $20.52 each
Clinuvel Pharmaceuticals (CUV) is progressing manufacturing of its adrenocorticotropic hormone (ACTH) product, NEURACTHEL.
The product will be made under current good manufacturing practices as the company finalises necessary work for a complete regulatory dossier.
ACTH is a human hormone in the melanocortins family and is used for a variety of bodily processes.
An injectable gel formulation of the hormone is approved in the US for the treatment of 19 different medical conditions.
The company identified a broader clinical potential for the hormone to treat neurological, endocrinological and degenerative disorders.
The company’s strategy is to develop and commercialise a broad suite of melanocortins. To achieve this it has engaged a manufacturing partner and strengthened its intellectual property portfolio.
Vice President of Scientific Affairs Dr Tim Zhao said the company is differentiating itself from other manufacturing groups by developing the use of NEURACTHEL.
“Not only are we focusing our knowledge on this family of bioactive peptides, but also widening the scope of use for ACTH, a potent hormone,” he said.
”We have a clear vision of what we are building towards and how to reach many patients in need.
“The huge advantage of our program is already the cumulative clinical exposure and experiences of this hormone in different regions and patient groups, such that there is available indicative safety and efficacy information from which we can build and derive novelty.”
Shares were trading 2 per cent higher at $20.52 at 2:36 pm AEDT.
